AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lennerstrand, J.
Right arrow Articles by Larder, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lennerstrand, J.
Right arrow Articles by Larder, B. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2001, p. 2144-2146, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2144-2146.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Biochemical Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to Stavudine

Johan Lennerstrand,1,* David K. Stammers,2 and Brendan A. Larder1,*

Virco UK, Ltd, Cambridge CB4 0GA,1 and Structural Biology Division, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN,2 United Kingdom

Received 18 December 2000/Returned for modification 9 March 2001/Accepted 25 April 2001

We have found a close correlation between viral stavudine (d4T) resistance and resistance to d4T-triphosphate at the human immunodeficiency virus type 1 reverse transcriptase (RT) level. RT from site-directed mutants with 69S-XX codon insertions and/or conventional zidovudine resistance mutations seems to be involved in an ATP-dependent resistance mechanism analogous to pyrophosphorolysis, whereas the mechanism for RT with the Q151M or V75T mutation appears to be independent of added ATP for reducing binding to d4T-triphosphate.

* Corresponding author. Mailing address for Brendan A. Larder: Virco UK, Ltd, 184 Cambridge Sciences Rd., Milton Rd., Cambridge CB4 0GA, United Kingdom. Phone: 44 1 223 728 828. Fax: 44 1 223 728 801. E-mail: brendan.larder{at}vircolab.com. Mailing address for Johan Lennerstrand: Division of Clinical Virology, F68, Huddinge University Hospital, 141 86 Stockholm, Sweden. Phone: 46 8 58581304. Fax: 46 8 58581305. E-mail: johan.lennerstrand{at}impi.ki.se.

Antimicrobial Agents and Chemotherapy, July 2001, p. 2144-2146, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2144-2146.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.